New radioactive therapy shows promise in early trial for tough cancers
NCT ID NCT05723640
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase trial tested a new radioactive drug called 177Lu-LNC1004 in 11 adults with advanced solid tumors that had stopped responding to standard treatments. The drug targets a protein (FAP) found on many cancer cells, delivering radiation directly to the tumor. The main goals were to check safety and find the right dose for future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
177Lu-LNC1004 (a radioactive drug that targets cancer cells)
What this could lead to
If successful, this could lead to a new treatment option for advanced solid tumors that have not responded to other therapies.
What could go wrong
This is a very early, small Phase 1 trial with only 11 participants, so results may not apply to everyone. The main goal is safety, not effectiveness, and there are risks from radiation exposure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, UNSPECIFIED, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National University Cancer Institute, Singapore National University Hospital, Singapore.
Singapore, 119077, Singapore